首页> 中国专利> 一种用于激活乳腺癌特异性免疫反应的试剂盒

一种用于激活乳腺癌特异性免疫反应的试剂盒

页面导航

摘要
著录项
法律信息
相似文献

摘要

本发明提供了一种用于激活乳腺癌特异性免疫反应的试剂盒，包括有RPMI-1640培养基、细胞培养上清、GM-CSF、IL-4、INFγ以及乳腺癌特异性抗原多肽组合；所述细胞培养上清为NK细胞与K562细胞共培养上清或者T细胞培养上清；所述乳腺癌特异性抗原多肽组合为MAGE-A1-A2、MAGE-A1-A3、NY-ESO-1-A2、PLAC1-A2、PIWIL2-A2、CEA-A2、CEA-A3、Mamaglobin-A-A3、NY-BR-1-A2、HER2-A2、HER2-A3及MTA1-A2；本发明的试剂盒可以高效地以主动诱导/被动诱导相结合的方式激活乳腺癌病人特异性的免疫反应。

著录项

公开/公告号CN105219728A

专利类型发明专利
公开/公告日2016-01-06

原文格式PDF
申请/专利权人上海隆耀生物科技有限公司;
展开▼

申请/专利号CN201510685141.6
发明设计人李伟;叶圣勤;汪鑫;瞿苏;
展开▼

申请日2015-10-20
分类号C12N5/0784;C12N5/0783;A61K39/00;A61P35/00;
代理机构上海申新律师事务所;
代理人竺路玲
地址 200070 上海市闸北区永和路118弄42号
入库时间 2023-12-18 13:33:31

法律信息

法律状态公告日

法律状态信息

法律状态
2020-02-18

发明专利申请公布后的驳回 IPC(主分类):C12N5/0784 申请公布日:20160106 申请日:20151020

发明专利申请公布后的驳回
2016-02-03

实质审查的生效 IPC(主分类):C12N5/0784 申请日:20151020

实质审查的生效
2016-01-06

公开

公开

相似文献

专利
中文文献
外文文献

1. 一种用于激活乳腺癌特异性免疫反应的试剂盒 [P] . 中国专利： CN105219728A . 2016-01-06
2. 一种用于激活前列腺癌特异性免疫反应的试剂盒 [P] . 中国专利： CN105219718A . 2016-01-06
3. isolated polynucleotide, expression cassette, host cell, isolated polypeptide, non-human transgenic animal that has been altered to express an alkali resistant mutant polypeptide, an antibody that specifically binds to an alkali resistant mutant polypeptide, a mutation detection kit alk inhibitor resistance in a biological sample, and methods for evaluating a biological sample for an alk inhibitor resistance mutation to diagnose cancer that is resistant to or likely to develop resistance to at least one alkaline inhibitor. small alk molecule kinase, to evaluate a biological sample for an alk inhibitor resistance mutation, to diagnose cancer that is resistant to or likely to develop resistance to pf-02341066 in a patient, to specifically reduce expression of an alk-resistant mutant to treat cancer associated with activating aberrant loop capacity that is resistant to at least one small molecule alk kinase inhibitor treating an aberrant cancer that is resistant to pf-02341066, identifyin [P] . BR112012026239A2 . 2018-06-26

机译：分离的多核苷酸，表达盒，宿主细胞，分离的多肽，已被改变以表达耐碱突变体多肽的非人类转基因动物，与耐碱突变体多肽特异性结合的抗体，突变检测试剂盒生物样品，以及用于评估生物样品中是否存在对烷基抑制剂的抗性突变以诊断对至少一种碱性抑制剂有抗药性或可能发展出抗药性的癌症的方法。小分子激酶，用于评估生物学样品中是否具有抑制碱性磷酸酶抑制剂的突变，以诊断对患者具有抗药性或可能对pf-02341066产生抗药性的癌症，从而特异性降低抗癌突变体的表达以治疗癌症与激活抗至少一种小分子烷基激酶抑制剂的异常环路能力有关，该抑制剂治疗对pf-02341066有抵抗力的异常癌症
4. Methods for treatment or prevention or prophylaxis of breast cancer, for detection, diagnosis and / or assessment or prognosis for breast cancer, for monitoring and / or estimation of breast cancer treatment, for identifying the presence or absence of breast cells metastatic breast cancer in a biological sample and for the evaluation or identification of compounds, uses of one or more bcmps, a composition, an antibody, nucleic acid and an agent that interacts with or modulates the activity of one or more bcmps , vaccine, composition, kit and antibody [P] . BR0108659A . 2002-11-05

机译：治疗或预防或预防乳腺癌，检测，诊断和/或评估或预后乳腺癌，监测和/或评估乳腺癌治疗，鉴定是否存在乳腺癌细胞转移性乳腺癌的方法生物样品并用于评估或鉴定化合物，一种或多种bcmps，组合物，抗体，核酸和与一种或多种bcmps相互作用或调节其活性的试剂，疫苗，组合物，试剂盒和抗体的用途
5. use of a compound selected from the group consisting of a proteasome inhibitor, an autophagy inhibitor, a lysosomal inhibitor, an golgi er protein transport inhibitor, an hsp90 chaperonin inhibitor, a heat shock response activator, a and a histone deacetylase inhibitor, use of 11-cis-retinal or 9-cis-retinal and a compound selected from the group consisting of a proteasome inhibitor, an autophagy inhibitor, a lissosomal inhibitor, a er to golgi protein, a hsp90 chaperonin inhibitor, a heat shock response activator, a glycosidase inhibitor, and a histone deacetylase inhibitor, a method for increasing the amount of a biochemically functional conformation of a protein in a cell, composition pharmaceutical for the treatment of an ocular pcd, pharmaceutical composition for the treatment of retinitis pigmentosa, kit for the treatment of an ocular pcd, kit for the treatment retinitis pigmentosa, method for identifying a compound useful for the treatment of an individual having an ocular pcd, [P] . BRPI0615962A2 . 2011-05-31

机译：使用选自以下的化合物：蛋白酶体抑制剂，自噬抑制剂，溶酶体抑制剂，高尔基体蛋白转运抑制剂，hsp90伴侣蛋白抑制剂，热休克反应激活剂，α和组蛋白脱乙酰酶抑制剂，使用11 -顺式-视黄醛或9-顺式-视黄醛以及选自蛋白酶体抑制剂，自噬抑制剂，核糖体抑制剂，高尔基体蛋白er，hsp90伴侣蛋白抑制剂，热休克反应激活剂，糖苷酶的化合物抑制剂和组蛋白脱乙酰基酶抑制剂，一种增加细胞中蛋白质的生化功能构象量的方法，用于治疗眼pcd的组合物药物，用于治疗色素性视网膜炎的药物组合物，用于治疗视网膜色素变性的试剂盒眼用pcd，用于治疗色素性视网膜炎的试剂盒，用于鉴定可用于治疗具有眼用pcd的个体的化合物的方法，